Navigating primary and secondary immunodeficiency intersections: how to find IEI hidden within SID

Area of Science:

• Immunology
• Oncology
• Genetics

Background:

• Primary immunodeficiencies (inborn errors of immunity, IEIs) and secondary immunodeficiencies (SIDs) share overlapping clinical features and diverse causes.
• IEIs stem from genetic defects, while SIDs are acquired, but both increase cancer risk, particularly hematological malignancies.
• Increasingly, immune deficiencies in cancer patients initially deemed secondary may be underlying IEIs.

Purpose of the Study:

• To provide a guide for identifying subtle clues of underlying IEIs in patients with hematological malignancies.
• To differentiate IEIs from SIDs in the context of cancer.
• To highlight the critical importance of this distinction for patient treatment and management.

Main Methods:

• Reviewing combinations of clinical features aligned with IEI manifestations.
• Analyzing laboratory markers, functional studies, and histological assessments.
• Evaluating genetic studies and atypical responses to therapy or malignancy features.

Main Results:

• Subtle clinical, laboratory, and genetic clues can unmask underlying IEIs in patients with hematological malignancies.
• Atypical responses to treatment and malignancy characteristics can indicate an underlying IEI.
• Distinguishing IEI from SID is critical for appropriate patient management.

Conclusions:

• Early and accurate identification of IEIs in cancer patients is essential.
• This distinction significantly impacts treatment approaches for both the immunodeficiency and the malignancy.
• Further research into the overlap between IEIs and hematological malignancies is warranted.